Test Catalog

Take Our Survey

Test ID: DAU    
Drug of Abuse Screen, DAU10, Urine

Useful For Suggests clinical disorders or settings where the test may be helpful

Detecting drug abuse involving amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, phencyclidine, tetrahydrocannabinol, and ethanol


This test is intended to be used in a setting where the test results can be used to make a definitive diagnosis.

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with screening tests for alcohol and drugs of abuse. Positives are confirmed and quantitated by definitive methods. Gas chromatography-mass spectrometry for amphetamines, barbiturates, benzodiazepines, cocaine and metabolites, phencyclidine, and tetrahydrocannabinol metabolite at an additional charge. Methadone and opiates that screen positive will be quantified with liquid chromatography-tandem mass spectrometry at an additional charge.


See Adulterant Survey Algorithm in Special Instructions.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

This test uses immunologic testing for drugs of abuse, by class, and screens for the presence of amphetamines, barbiturates, benzodiazepines, cocaine metabolite, methadone, opiates, phencyclidine, tetrahydrocannabinol, and ethanol. Positive immunologic results are confirmed by gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry with the exception of ethanol. Positive ethanol results are reported quantitatively directly from immunologic testing.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.


The specific drug identified will be reported.


Enzyme-multiplied immunoassay technique cutoff concentrations:

Amphetamines: 500 ng/mL

Barbiturates: 200 ng/mL

Benzodiazepines: 200 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Methadone: 300 ng/mL

Opiates: 300 ng/mL

Phencyclidine: 25 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL

Ethanol: 10 mg/dL

Results of this test are confirmed and should be considered definitive.

Interpretation Provides information to assist in interpretation of the test results

A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, DAUAM / Drugs of Abuse, Amphetamines GC-MS Confirmation, Urine) for more information.


For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at http://www.mayomedicallaboratories.com/articles/drug-book/index.html


Creatinine and specific gravity are measured as indicators of specimen dilution.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Not intended for use in employment-related testing.


The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (CDAS / Drug Screen, Prescription/OTC, Serum or CDAUN / Drug Screen, Prescription/OTC, Urine).

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

Porter WF, Moyer TP: Clinical toxicology. In Tietz Textbook of Clinical Chemistry. Fourth edition. Edited by CA Burtis, ER Ashwood. Philadelphia, PA, WB Saunders Company, 1993, pp 1155-1235

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test